That is just one (for patients with compensated cirrhosis) of several studies. For patients with absence of cirrhosis, here is the study (from investigator) - ritonavir dosage is 100mg QD:
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ ABT 267 (ABT-450/r/ABT-267) and ABT-333 Co-administered with Ribavirin (RBV) in Treatment Naïve Adults with Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (SAPPHIRE-I)
? Treatment naïve adults between 18 – 70 y/o with a BMI = 18 to < 38 kg/m2
? Liver biopsy within 24 months of screening showing absence of cirrhosis or a FibroTest score of = 0.72 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) = 2 Approximately 600 HCV genotype 1-infected, treatment-naive adults will be randomized to Arms A and B in a 3:1 ratio in the Double-blind (DB) Treatment Period. Randomization will be stratified by HCV subtype (1a versus non-la) and interleukin 28B (IL28B) genotype (CC versus non-CC). This study will consist of three periods: the DB Treatment Period, an Openlabel (OL) Treatment Period for previous placebo subjects, and a Post-Treatment (PT) Period for all subjects who received active drugs.
Arm A: ABT-450/r/ABT-267 150 mg /100 mg /25 mg once daily (QD) + ABT-333 250 mg twice daily (BID) with weight-based RBV BID for 12 weeks;
Arm B: Placebo for ABT-450/r/ABT-267 150 mg /100 mg /25 mg QD + Placebo for ABT-333 250 mg BID with weight-based Placebo for RBV BID for 12 weeks followed by ABT-450/r/ABT-267 150 mg /100 mg /25 mg QD + ABT-333 250 mg BID with weight-based RBV BID for 12 weeks
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.